Hang Likang: Currently, there is only one innovative drug project under research.

Jin10 Data July 1st, Anglikon released an announcement regarding abnormal fluctuations in stock trading. The company has noticed that the market's attention on innovative drug business has been relatively high recently. Currently, the company has only one innovative drug project under research, which is the ALK-N001 project. This project received a notice of approval for clinical trials in April 2025, and as of the date of this announcement, it is still in the Phase I clinical trial stage. The development of innovative drugs is characterized by long cycles, high investment, and high uncertainty, and investors are advised to pay attention to investment risks.

View Original
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Share
Comment
0/400
No comments
Trade Crypto Anywhere Anytime
qrCode
Scan to download Gate app
Community
English
  • 简体中文
  • English
  • Tiếng Việt
  • 繁體中文
  • Español
  • Русский
  • Français (Afrique)
  • Português (Portugal)
  • Bahasa Indonesia
  • 日本語
  • بالعربية
  • Українська
  • Português (Brasil)